Recombinant Mouse IFN-kappa Protein

R&D Systems, part of Bio-Techne | Catalog # 8437-MK

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Carrier Free
8437-MK-010/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
8437-MK-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

Q7TSL0

Conjugate

Unconjugated

Applications

Bioactivity

View all IFN-kappa Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse IFN-kappa protein
Leu22-Lys199

Purity

>95%, by SDS-PAGE with silver staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu22

Predicted Molecular Mass

21 kDa

SDS-PAGE

19-22 kDa, reducing conditions

Activity

Measured in an anti-viral assay using L-929 mouse fibroblast cells infected with encephalomyocarditis (EMC) virus. Vogel, S.N. et al. (1982) Infect. Immunol. 38:681.
The ED50 for this effect is 0.2-1.2 ng/mL.

Scientific Data Images for Recombinant Mouse IFN-kappa Protein

Recombinant Mouse IFN-kappa Protein Bioactivity

Recombinant Mouse IFN-kappa Protein Bioactivity

Recombinant Mouse IFN-kappa (Catalog # 8437-MK) exhibits anti-viral activity in L‑929 mouse fibroblast cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 0.2-1.2 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 8437-MK
Formulation Lyophilized from a 0.2 μm filtered solution in Sodium Acetate, NaCl and EDTA with BSA as a carrier protein.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 8437-MK/CF
Formulation Lyophilized from a 0.2 μm filtered solution in Sodium Acetate, NaCl and EDTA.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-kappa

Interferon (IFN)-kappa is a member of the type I IFN family, which also includes IFN-alpha, -beta, -epsilon, and -omega. Mouse IFN-kappa is expressed at low levels in peritoneal macrophages and its expression is up-regulated by double-stranded (ds) RNA and IFN-gamma (1). Mice over-expressing IFN-kappa in pancreatic beta cells developed type I diabetes, similar to what has been reported for mice over-expressing IFN-alpha, -beta, and -gamma (1-4). Mouse IFN-kappa shares 68% and 30% amino acid sequence identity with rat and human IFN-kappa, respectively. Human IFN-kappa has been detected in keratinocytes, monocytes, and monocyte-derived dendritic cells and is reported to have contact-dependent antiviral activity (5-7). Human papillomavirus (HPV) 16 oncogene expression, which is necessary for the development of cervical cancer, has been shown to down-regulate human IFN-kappa expression (8-11).

References

  1. Vassileva, G. et al. (2003) J. Immunol. 170:5748.
  2. Stewart, T.A. et al. (1993) Science 260:1942.
  3. Sarvetnick, N. et al. (1988) Cell 52:773.
  4. Pelegrin, M. et al. (1998) J. Biol. Chem. 273:12332.
  5. LaFleur, D.W. et al. (2001) J. Biol. Chem. 276:39765.
  6. Nardelli, B. et al. (2002) J. Immunol. 169:4822.
  7. Buontempo, P.J. et al. (2006) J. Interferon Cytokine Res. 26:40.
  8. Rincon-Orozco, B. et al. (2009) Cancer Res. 69:8718.
  9. DeCarlo, C.A. et al. (2010) Lab. Invest. 90:1482.
  10. Reiser, J. et al. (2011) J. Virol. 85:11372.
  11. Sunthamala, N. et al. (2014) PLoS One 9:e91473.

Long Name

Interferon kappa

Alternate Names

IFNK, IFNkappa

Entrez Gene IDs

56832 (Human); 387510 (Mouse)

Gene Symbol

IFNK

UniProt

Q7TSL0

Additional IFN-kappa Products

Product Documents for Recombinant Mouse IFN-kappa Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 8437-MK (with carrier)
Download SDS 8437-MK/CF (carrier free)

Product Specific Notices for Recombinant Mouse IFN-kappa Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.